Home › Entities › clinical_trial › Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

clinical trial
MedicalStudy clinical_trial Q99956128
Press Enter · cited answer in seconds

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Summary

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 is a clinical trial[1].

Key Facts

  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 is in the country of Russia[2].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's instance of is recorded as clinical trial[3].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's start time is recorded as +2020-09-11T00:00:00Z[4].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's end time is recorded as +2020-11-30T00:00:00Z[5].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's sponsor is recorded as CanSino Biologics[6].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's number of participants is recorded as {'unit': '1', 'amount': '+500'}[7].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's title is recorded as Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers[8].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's uses is recorded as partial thromboplastin time[9].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[10].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's ClinicalTrials.gov ID is recorded as NCT04540419[11].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+85'}[12].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's clinical trial phase is recorded as phase III clinical trial[13].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's research subject recruitment status is recorded as recruiting[14].
  • Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19's study type is recorded as interventional study[15].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . clinicaltrials.gov. Retrieved . clinicaltrials.gov. Provenance: wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . clinicaltrials.gov. Retrieved . clinicaltrials.gov. Provenance: wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19. Retrieved May 3, 2026, from https://4ort.xyz/entity/clinical-trial-of-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-against-covid-19
MLA “Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/clinical-trial-of-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-against-covid-19.
BibTeX @misc{4ortxyz_clinical-trial-of-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-against-covid-19_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19}}, year = {2026}, url = {https://4ort.xyz/entity/clinical-trial-of-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-against-covid-19}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 — https://4ort.xyz/entity/clinical-trial-of-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-against-covid-19 (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/clinical-trial-of-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-against-covid-19 · Last refreshed: